Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study
<p>Abstract</p> <p>Background</p> <p>Previous randomized studies have demonstrated that fesoterodine significantly improves the Overactive Bladder (OAB) symptoms and their assessment by patients compared with tolterodine extended-release (ER). This study aimed to assess...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-07-01
|
| Series: | BMC Urology |
| Subjects: | |
| Online Access: | http://www.biomedcentral.com/1471-2490/12/19 |
| _version_ | 1828490470056001536 |
|---|---|
| author | Castro-Diaz David Miranda Pilar Sanchez-Ballester Francisco Lizarraga Isabel Arumí Daniel Rejas Javier |
| author_facet | Castro-Diaz David Miranda Pilar Sanchez-Ballester Francisco Lizarraga Isabel Arumí Daniel Rejas Javier |
| author_sort | Castro-Diaz David |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Previous randomized studies have demonstrated that fesoterodine significantly improves the Overactive Bladder (OAB) symptoms and their assessment by patients compared with tolterodine extended-release (ER). This study aimed to assess the effect of aging and dose escalation on patient-reported treatment benefit, after changing their first Overactive Bladder (OAB) therapy with tolterodine-ER to fesoterodine in daily clinical practice.</p> <p>Methods</p> <p>A post-hoc analysis of data from a retrospective, cross-sectional and observational study was performed in a cohort of 748 OAB adults patients (OAB-V8 score ≥8), who switched to fesoterodine from their first tolterodine-ER-based therapy within the 3–4 months before study visit. Effect of fesoterodine doses (4 mg vs. 8 mg) and patient age (<65 yr vs. ≥65 yr) were assessed. Patient reported treatment benefit [Treatment Benefit Scale (TBS)] and physician assessment of improvement with change [Clinical Global Impression of Improvement subscale (CGI-I)] were recorded. Treatment satisfaction, degree of worry, bother and interference with daily living activities due to urinary symptoms were also assessed.</p> <p>Results</p> <p>Improvements were not affected by age. Fesoterodine 8 mg vs. 4 mg provides significant improvements in terms of treatment benefit [TBS 97.1% vs. 88.4%, p < 0.001; CGI-I 95.8% vs. 90.8% p < 0.05)], degree of worry, bother and interference with daily-living activities related to OAB symptoms (p <0.05).</p> <p>Conclusions</p> <p>A change from tolterodine ER therapy to fesoterodine with dose escalation to 8 mg in symptomatic OAB patients, seems to be associated with greater improvement in terms of both patient-reported-treatment benefit and clinical global impression of change. Improvement was not affected by age.</p> |
| first_indexed | 2024-12-11T10:44:11Z |
| format | Article |
| id | doaj.art-bd7ad89b7b554435882ecef00f5e40ce |
| institution | Directory Open Access Journal |
| issn | 1471-2490 |
| language | English |
| last_indexed | 2024-12-11T10:44:11Z |
| publishDate | 2012-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Urology |
| spelling | doaj.art-bd7ad89b7b554435882ecef00f5e40ce2022-12-22T01:10:31ZengBMCBMC Urology1471-24902012-07-011211910.1186/1471-2490-12-19Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective studyCastro-Diaz DavidMiranda PilarSanchez-Ballester FranciscoLizarraga IsabelArumí DanielRejas Javier<p>Abstract</p> <p>Background</p> <p>Previous randomized studies have demonstrated that fesoterodine significantly improves the Overactive Bladder (OAB) symptoms and their assessment by patients compared with tolterodine extended-release (ER). This study aimed to assess the effect of aging and dose escalation on patient-reported treatment benefit, after changing their first Overactive Bladder (OAB) therapy with tolterodine-ER to fesoterodine in daily clinical practice.</p> <p>Methods</p> <p>A post-hoc analysis of data from a retrospective, cross-sectional and observational study was performed in a cohort of 748 OAB adults patients (OAB-V8 score ≥8), who switched to fesoterodine from their first tolterodine-ER-based therapy within the 3–4 months before study visit. Effect of fesoterodine doses (4 mg vs. 8 mg) and patient age (<65 yr vs. ≥65 yr) were assessed. Patient reported treatment benefit [Treatment Benefit Scale (TBS)] and physician assessment of improvement with change [Clinical Global Impression of Improvement subscale (CGI-I)] were recorded. Treatment satisfaction, degree of worry, bother and interference with daily living activities due to urinary symptoms were also assessed.</p> <p>Results</p> <p>Improvements were not affected by age. Fesoterodine 8 mg vs. 4 mg provides significant improvements in terms of treatment benefit [TBS 97.1% vs. 88.4%, p < 0.001; CGI-I 95.8% vs. 90.8% p < 0.05)], degree of worry, bother and interference with daily-living activities related to OAB symptoms (p <0.05).</p> <p>Conclusions</p> <p>A change from tolterodine ER therapy to fesoterodine with dose escalation to 8 mg in symptomatic OAB patients, seems to be associated with greater improvement in terms of both patient-reported-treatment benefit and clinical global impression of change. Improvement was not affected by age.</p>http://www.biomedcentral.com/1471-2490/12/19Overactive bladderFesoterodineTolterodine ERDose escalationAgePatient-reported treatment benefit |
| spellingShingle | Castro-Diaz David Miranda Pilar Sanchez-Ballester Francisco Lizarraga Isabel Arumí Daniel Rejas Javier Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study BMC Urology Overactive bladder Fesoterodine Tolterodine ER Dose escalation Age Patient-reported treatment benefit |
| title | Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study |
| title_full | Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study |
| title_fullStr | Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study |
| title_full_unstemmed | Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study |
| title_short | Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study |
| title_sort | dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine er to fesoterodine post hoc analysis from an observational and retrospective study |
| topic | Overactive bladder Fesoterodine Tolterodine ER Dose escalation Age Patient-reported treatment benefit |
| url | http://www.biomedcentral.com/1471-2490/12/19 |
| work_keys_str_mv | AT castrodiazdavid doseandagingeffectonpatientsreportedtreatmentbenefitswitchingfromthefirstoveractivebladdertherapywithtolterodineertofesoterodineposthocanalysisfromanobservationalandretrospectivestudy AT mirandapilar doseandagingeffectonpatientsreportedtreatmentbenefitswitchingfromthefirstoveractivebladdertherapywithtolterodineertofesoterodineposthocanalysisfromanobservationalandretrospectivestudy AT sanchezballesterfrancisco doseandagingeffectonpatientsreportedtreatmentbenefitswitchingfromthefirstoveractivebladdertherapywithtolterodineertofesoterodineposthocanalysisfromanobservationalandretrospectivestudy AT lizarragaisabel doseandagingeffectonpatientsreportedtreatmentbenefitswitchingfromthefirstoveractivebladdertherapywithtolterodineertofesoterodineposthocanalysisfromanobservationalandretrospectivestudy AT arumidaniel doseandagingeffectonpatientsreportedtreatmentbenefitswitchingfromthefirstoveractivebladdertherapywithtolterodineertofesoterodineposthocanalysisfromanobservationalandretrospectivestudy AT rejasjavier doseandagingeffectonpatientsreportedtreatmentbenefitswitchingfromthefirstoveractivebladdertherapywithtolterodineertofesoterodineposthocanalysisfromanobservationalandretrospectivestudy |